Health Risk

Representative Image. Glenmark building, blue glass facade. Photo Source: Glenmark Pharma.

Glenmark Recalls 1.5M ADHD Drug Bottles Over Carcinogen Risk

Glenmark Pharmaceuticals has recalled approximately 1.5 million bottles of Atomoxetine Capsules from the US market after tests found potentially harmful impurities above FDA-approved limits. The medication, used to treat attention deficit hyperactivity disorder (ADHD), was recalled on January 29, 2025.
March 3, 2025